on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Oxford Biomedica
The Vanguard Group, Inc. has filed Form 8.3 regarding its position in Oxford Biomedica plc. As of February 13, 2026, Vanguard holds an interest amounting to 1,211,518 ordinary shares, representing 1% of the company's relevant securities. This disclosure complies with Rule 8.3 of the Takeover Code, indicating significant interest in the firm.
The form also notes that there have been sales transactions involving 7,506 ordinary shares at a price of 8.23 GBP per unit. Additionally, Vanguard affirms no indemnity or option arrangements exist that might influence its dealings with Oxford Biomedica's securities.
This disclosure reflects transparency in Vanguard's investment activities and adherence to regulatory requirements.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news